BR0314089A - Sacarìdeos modificados, conjugados do mesmo e sua fabricação - Google Patents

Sacarìdeos modificados, conjugados do mesmo e sua fabricação

Info

Publication number
BR0314089A
BR0314089A BR0314089-0A BR0314089A BR0314089A BR 0314089 A BR0314089 A BR 0314089A BR 0314089 A BR0314089 A BR 0314089A BR 0314089 A BR0314089 A BR 0314089A
Authority
BR
Brazil
Prior art keywords
conjugates
linker
new
manufacture
modified saccharides
Prior art date
Application number
BR0314089-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Aldo Giannozzi
Francesco Norelli
Paolo Costantino
Giovanni Averani
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BR0314089A publication Critical patent/BR0314089A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314089-0A 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação BR0314089A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Publications (1)

Publication Number Publication Date
BR0314089A true BR0314089A (pt) 2005-11-16

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314089-0A BR0314089A (pt) 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação

Country Status (16)

Country Link
US (2) US8895516B2 (https=)
EP (1) EP1534342B1 (https=)
JP (2) JP5268222B2 (https=)
CN (2) CN1688343B (https=)
AT (1) ATE319481T1 (https=)
AU (1) AU2003260921B2 (https=)
BR (1) BR0314089A (https=)
CA (1) CA2497167C (https=)
DE (1) DE60303961T2 (https=)
DK (1) DK1534342T3 (https=)
ES (1) ES2260682T3 (https=)
GB (1) GB0220198D0 (https=)
MX (1) MXPA05002315A (https=)
NZ (1) NZ538703A (https=)
RU (2) RU2005108992A (https=)
WO (1) WO2004019992A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
ES2533248T3 (es) * 2005-05-06 2015-04-08 Novartis Ag Inmunógenos para vacunas contra Meningitidis A
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BR112012010223A2 (pt) * 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 rLP2086 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
EP3104886B1 (en) * 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107810273B (zh) * 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
KR102428253B1 (ko) * 2016-03-15 2022-08-02 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 신규한 다당류-단백질 접합체 및 이의 제조방법
KR102906912B1 (ko) 2016-09-02 2026-01-05 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
EP3934696A1 (en) * 2019-03-08 2022-01-12 GlaxoSmithKline Biologicals S.A. Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
EP0737203A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Steroidal glycosides
CA2189356A1 (en) * 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
US6472506B1 (en) * 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
CA2266718C (en) * 1997-08-08 2007-05-22 Behringwerke Aktiengesellschaft Polysaccharide conjugates of biomolecules
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
PT1777236T (pt) 2002-03-26 2017-02-13 Glaxosmithkline Biologicals Sa Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
WO2004019992A1 (en) 2004-03-11
DE60303961T2 (de) 2006-10-26
DE60303961D1 (de) 2006-05-04
US20060263390A1 (en) 2006-11-23
CA2497167A1 (en) 2004-03-11
AU2003260921B2 (en) 2008-03-06
NZ538703A (en) 2006-09-29
ES2260682T3 (es) 2006-11-01
CN101863998A (zh) 2010-10-20
CN1688343A (zh) 2005-10-26
GB0220198D0 (en) 2002-10-09
EP1534342B1 (en) 2006-03-08
CN101863998B (zh) 2012-08-29
RU2531909C2 (ru) 2014-10-27
JP5268222B2 (ja) 2013-08-21
EP1534342A1 (en) 2005-06-01
RU2008150551A (ru) 2010-06-27
JP5314745B2 (ja) 2013-10-16
US20150166593A1 (en) 2015-06-18
ATE319481T1 (de) 2006-03-15
DK1534342T3 (da) 2006-07-10
AU2003260921A1 (en) 2004-03-19
MXPA05002315A (es) 2005-06-08
CA2497167C (en) 2011-07-12
US8895516B2 (en) 2014-11-25
CN1688343B (zh) 2010-09-08
JP2006511465A (ja) 2006-04-06
RU2005108992A (ru) 2005-11-10
JP2012017342A (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
BR0314089A (pt) Sacarìdeos modificados, conjugados do mesmo e sua fabricação
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
RU2412944C2 (ru) Иммуногены для вакцин против менингита а
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
JP2005532287A5 (https=)
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
UA95237C2 (uk) Імуногенна композиція
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
ATE306261T1 (de) Antithrombosemittel
PT751144E (pt) Novos pro-farmacos antraciclinicos, metodo para preparacao e tambem a sua utilizacao em quimioterapia selectiva
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
ATE464066T1 (de) Neisseria meningitidis igtb los als adjuvans
DK0989972T3 (da) Farmaceutiske prostaglandinsammensætninger
ATE503746T1 (de) Neue imidazolidinderivate
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
GB0501964D0 (en) Chemical compounds
TR200402546T4 (tr) Taksan türevleri hazırlamak için işlem.
EP1996217A4 (en) NOVEL ANTIBIOTIC COMPOSITIONS
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
WO2001079170A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L. (IT)

Free format text: ALTERADO DE: CHIRON SRL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07H 13/12 (2006.01), A61K 47/64 (2017.01)

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/715 (2006.01), A61K 47/64 (2017.01), C07H

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements